Should Platelets Be Ordered Leukocyte-Reduced and Irradiated?
Platelets should routinely be ordered leukocyte-reduced for all patients, as this is now the standard practice in the United States and most developed countries, while irradiation should be selectively ordered only for specific high-risk patient populations.
Leukocyte Reduction
Leukocyte-reduced platelets are now the standard product in the United States and should be used universally. 1 The overwhelming majority of blood products are now leukoreduced at the time of collection and component preparation, making this a default rather than a special order in most institutions.
Benefits of Universal Leukoreduction:
- Substantially reduces transfusion reactions 1
- Reduces transmission of cytomegalovirus (CMV) infection 1
- Decreases alloimmune refractoriness to platelet transfusion (4% vs 14% in non-leukoreduced products) 1
- Most apheresis platelet products now contain <5 × 10⁶ leukocytes and are considered leukocyte-reduced 1
Clinical implication: In most modern blood banks, you do not need to specifically order "leukocyte-reduced" platelets as this is already the standard product. However, verify your institution's practices.
Irradiation - Selective Use Only
Irradiation should NOT be routinely ordered for all patients. 1 Irradiation is indicated only for specific high-risk populations to prevent transfusion-associated graft-versus-host disease (TA-GVHD), a rare but usually fatal complication.
Definite Indications for Irradiated Platelets:
- Recipients of autologous and allogeneic stem-cell transplants 1
- Patients receiving blood products from partially matched family members 1
- Patients with severe immunosuppression from specific conditions:
- Hodgkin's lymphoma 1
- Patients receiving markedly immunosuppressive therapy:
When Irradiation is NOT Indicated:
- Patients with acute leukemia receiving standard therapies 1
- Patients with AIDS 1
- Patients with solid tumors 1
Technical Specifications:
- Minimum dose of 25 Gy is recommended 1
- Leukocyte depletion alone does NOT eliminate the risk of TA-GVHD 1—irradiation is still required for high-risk patients even with leukoreduced products
Critical Practice Considerations
Common Pitfall:
A 2014 College of American Pathologists survey found that at least 30% of centers were NOT irradiating products for patients with consensus indications 1. This represents a significant patient safety issue.
Action item: Verify your institution's irradiation policies and ensure they align with guidelines. Some cancer centers with multiple providers have adopted universal irradiation for all patients to guarantee vulnerable recipients receive appropriate products, though this is not evidence-based for low-risk patients. 1
Logistical Reality:
Most smaller centers lack blood irradiators and must send products to regional centers for irradiation, which can delay transfusion availability. 1 Plan ahead for patients requiring irradiated products.
Emerging Technology:
UV irradiation pathogen reduction technologies may damage lymphocyte DNA sufficiently to prevent TA-GVHD, potentially eliminating the need for gamma irradiation in the future. 1 However, this is not yet standard practice.
Practical Ordering Algorithm
For leukocyte reduction: Order standard platelets (already leukoreduced in most US institutions)
For irradiation, assess patient risk:
- High risk (stem-cell transplant, Hodgkin's, fludarabine, family donor) → Order irradiated platelets
- Standard risk (acute leukemia on standard therapy, solid tumors, AIDS) → Order standard (non-irradiated) platelets
- When uncertain → Consult with transfusion medicine service
Communicate with your blood bank about patients requiring irradiated products to ensure timely availability 1